Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: FASEB J. 2020 Mar 5;34(4):5877–5891. doi: 10.1096/fj.201903045RR

Fig 6.

Fig 6.

Enz plus Olaparib can lead to better suppression of the HCC growth in vivo. A) SK-HEP-1-luc orthotopic xenografted HCC model was established and mice treated with Enz (ENZ) or Olaparib (OLA) alone and in combination. Bioluminescent images record weekly tumor growth in different groups (three mice in each group). B) Tumor growth was analyzed by relative emission of photons (left). Synergy analyses using Bliss independence model and two-way ANOVA analysis (right). C) Immunohistochemcal staining for BRCA1 (upper), Ki67 (middle) and cleaved caspase-3 (lower), quantitations on the right. For C, quantitation data are at the right. Data are presented as mean ± SD. *P < 0.05. Scale bar 100 μm.